Testing a Personalised Care Plan App for People With Melanoma
Tests a phone app giving personalised care information to adults with early-stage skin melanoma.
Plain-language title generated from the registry record
Registry title: Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma
Key facts
- Where
- Dordrecht and Rotterdam, NetherlandsSee the 4 sites
Where in Netherlands
- Albert Schweitzer HospitalDordrecht, NetherlandsTaking people
- Erasmus MCRotterdam, NetherlandsTaking people
- Franciscus Gasthuis & Vlietland hospitalRotterdam, NetherlandsNot yet recruiting
- Maasstad HospitalRotterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Erasmus Medical Center
- Trial code
- NCT06643286
- Record updated
- 11 June 2025
- Original description
A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app. A total of hundred-eighty melanoma patients (stage I and II) will be randomised to receive either the SCP Melanoma app or usual care. The app provides survivors with personalized healthcare information on diagnosis, treatment and follow-up and supportive care, tailored to their melanoma stage and phase and information needs.Through questionnaires, medical file records, patient-reported outcomes and use of medical care will be evaluated. In addition, log-data, questionnaires and interviews will be used to evaluate the process of the uptake and implementation of the digital SCP.Read full original descriptionShow less
Personalised Survivorship Care for Patients With Melanoma: A Multicenter Randomised Controlled Trial of the Survivorship Care Plan App
A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app. A total of hundred-eighty melanoma patients (stage I and II) will be randomised to receive either the SCP Melanoma app or usual care. The app provides survivors with personalized healthcare information on diagnosis, treatment and follow-up and supportive care, tailored to their melanoma stage and phase and information needs.Through questionnaires, medical file records, patient-reported outcomes and use of medical care will be evaluated. In addition, log-data, questionnaires and interviews will be used to evaluate the process of the uptake and implementation of the digital SCP.
Inclusion: 18 years or older; Patients who have received a primary diagnosis of cutaneous melanoma stage I to II in the past 0-4 months.
Exclusion: Patients with irresectable stage III melanoma, patients receiving neo-adjuvant treatment and patients with stage IV melanoma; Patients who do not have (sufficient) command of the Dutch language.